Skip to main content
Download PDF

Subcutaneous immunoglobulin replacement therapy with Hizentra®, the first 20% SCIG preparation: a Practical approach

Advances in Therapy volume 28, Article number: 521 (2011) Cite this article

Abstract

To reduce the risk of infection in adults and children with primary immunodeficiencies, replacement therapy with IgG, which can be administered to patients intravenously or subcutaneously, is required. Although intravenous administration of IgG (IVIG) has been the therapy of choice in the US and widely used in Europe for many years, subcutaneous administration of IgG (SCIG) has recently gained considerable acceptance among patients and doctors. SCIG therapy achieves high and stable serum IgG levels, is well tolerated, and can be self-administered. Hizentra® (IgPro20; CSL Behring, Berne, Switzerland) is the first, ready-to-use 20% liquid preparation of human IgG specifically formulated for subcutaneous infusions. The high concentration (20%) might allow shorter infusion times due to smaller infusion volumes, with potential improvement in the convenience of SCIG therapy. Hizentra is well tolerated and has been shown to protect adult and pediatric primary immunodeficiency patients against serious bacterial infections. In addition, it is easy to handle and can be stored at a temperature up to 25°C. In summary, Hizentra is an advance in the field of immunoglobulin replacement therapy, which might offer benefits for home therapy patients.

References

  1. Buckley RH. Primary immunodeficiency diseases due to defects in lymphocytes. N Engl J Med. 2000;343:1313–1324.

    PubMed  Article  CAS  Google Scholar 

  2. Notarangelo LD, Fischer A, Geha RS, et al. Primary immunodeficiencies: 2009 update. J Allergy Clin Immunol. 2009;124:1161–1178.

    PubMed  Article  CAS  Google Scholar 

  3. Bruton OC. Agammaglobulinemia. Pediatrics. 1952;9:722–728.

    PubMed  CAS  Google Scholar 

  4. Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. Bio Drugs. 2007;21:105–116.

    CAS  Google Scholar 

  5. Moore ML, Quinn JM. Subcutaneous immunoglobulin replacement therapy for primary antibody deficiency: advancements into the 21st century. Ann Allergy Asthma Immunol. 2008;101:114–121.

    PubMed  Article  CAS  Google Scholar 

  6. Ochs HD, Gupta S, Kiessling P, Nicolay U, Berger M. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol. 2006;26:265–273.

    PubMed  Article  CAS  Google Scholar 

  7. Bexon M, Rojavin M, Jolles S, Ellis S, Sawyer J. The construction of a pharmacokinetic model to describe intravenous and subcutaneous supplementation of IgG in patients with primary immunodeficiency (PID) [abstract]. J Allergy Clin Immunol. 2011;127:AB16.

    Article  Google Scholar 

  8. Gardulf A, Nicolay U, Asensio O, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies—a prospective, multi-national study. J Clin Immunol. 2006;26:177–185.

    PubMed  Article  CAS  Google Scholar 

  9. Gardulf A, Nicolay U. Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficiencies. Curr Opin Allergy Clin Immunol. 2006;6:434–442.

    PubMed  Article  Google Scholar 

  10. Hagan JB, Fasano MB, Spector S, et al. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J Clin Immunol. 2010;30:734–745.

    PubMed  Article  CAS  Google Scholar 

  11. Jolles S, Bernatowska E, de Gracia J, et al. Efficacy and safety of Hizentra® in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy. Clin Immunol. 2011. In press.

  12. CSL Behring. ZLB06_003CR — A single-center, randomized, single-blind, 2-way cross-over study to compare the safety of intravenous (IV) administration of 10% (IgPro10, Privigen®) and 20% (IgPro20) liquid human immunoglobulin. Marburg, Germany: CSL Behring GmbH; 2008.

    Google Scholar 

  13. Maeder W, Lieby P, Sebald A, et al. Local tolerance and stability up to 24 months of a new 20% proline-stabilized polyclonal immunoglobulin for subcutaneous administration. Biologicals. 2011;39:43–49.

    PubMed  Article  CAS  Google Scholar 

  14. Bolli R, Woodtli L, Bärtschi M, Höfferer L, Lerch P. l-Proline reduces IgG dimer content and enhances the stability of intravenous immunoglobulin (IVIG) solutions. Biologicals. 2010;38:150–157

    PubMed  Article  CAS  Google Scholar 

  15. Stucki M, Boschetti N, Schaefer W, et al. Investigations of prion and virus safety of a new liquid IVIG product. Biologicals. 2008;36:239–247.

    PubMed  Article  CAS  Google Scholar 

  16. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Q1A (R2): stability testing of new drug substances and products; Feb 6, 2003. Available at: www.ich.org. Accessed April 2011.

  17. CSL Behring. Benefits of Hizentra. Available at: www.hizentra.com/consumer/about-hizentra/benefits-of-hizentra.aspx. Accessed April 2011.

  18. CSL Behring. IgPro20, US prescribing information. Marburg, Germany: CSL Behring GmbH; 2009.

    Google Scholar 

  19. Hughes RA, Dalakas MC, Cornblath DR, et al. Clinical applications of intravenous immunoglobulins in neurology. Clin Exp Immunol. 2009;158(Suppl 1):34–42.

    PubMed  Article  CAS  Google Scholar 

  20. Eftimov F, Vermeulen M, de Haan RJ, van den Berg LH, van Schaik IN. Subcutaneous immunoglobulin therapy for multifocal motor neuropathy. J Peripher Nerv Syst. 2009;14:93–100.

    PubMed  Article  CAS  Google Scholar 

  21. Harbo T, Andersen H, Hess A, et al. Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. Eur J Neurol. 2009;16:631–638.

    PubMed  Article  CAS  Google Scholar 

  22. Harbo T, Andersen H, Jakobsen J. Long-term therapy with high doses of subcutaneous immunoglobulin in multifocal motor neuropathy. Neurology, 2010;75:1377–1380.

    PubMed  Article  CAS  Google Scholar 

  23. Misbah S, Baumann A, Fazio R, et al. A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglobulin therapy. An open-label proof-of-concept study. J Peripher Nerv Syst. 2011. In press.

  24. Danieli MG, Pettinari L, Moretti R, Logullo F, Gabrielli A. Subcutaneous immunoglobulin in polymyositis and dermatomyositis: A novel application. Autoimmun Rev. 2011;10:144–149.

    PubMed  Article  Google Scholar 

  25. Wasserman R, Melamed I, Nelson RP Jr., et al. Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency. Clin Pharmacokinetics. 2011;50:405–414.

    Article  Google Scholar 

  26. Gardulf A, Andersen V, Bjorkander J, et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet. 1995;345:365–369.

    PubMed  Article  CAS  Google Scholar 

  27. Sneller MC, Strober W, Eisenstein E, Jaffe JS, Cunningham Rundles C. New insights into common variable immunodeficiency. Ann Intern Med. 1993;118:720–730.

    PubMed  CAS  Google Scholar 

  28. Duff CM, Faulkner E, Schirm Z, et al. Effective use of subcutaneous immune globulin (SCIG) for an infant with X-linked agammaglobulinemia (X-LA) [abstract]. J Allergy Clin Immunol. 2009;123:S64.

    Article  Google Scholar 

  29. Fasth A, Nystrom J. Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency. Acta Paediatr. 2007;96:1474–1478.

    PubMed  Article  Google Scholar 

  30. Gaspar J, Gerritsen B, Jones A. Immunoglobulin replacement treatment by rapid subcutaneous infusion. Arch Dis Child. 1998;79:48–51.

    PubMed  Article  CAS  Google Scholar 

  31. Hoffmann F, Grimbacher B, Thiel J, Peter HH, Belohradsky BH. Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency. Eur J Med Res. 2010;15:238–245.

    PubMed  CAS  Google Scholar 

  32. Borte M, Bernatowska E, Ochs HD, Roifman CM. Efficacy and safety of home-based subcutaneous immunoglobulin replacement therapy in paediatric patients with primary immunodeficiencies. Clin Exp Immunol. 2011;164:357–364.

    PubMed  Article  CAS  Google Scholar 

  33. Gardulf A, Bjorvell H, Gustafson R, Hammarstrom L, Smith CI. The life situations of patients with primary antibody deficiency untreated or treated with subcutaneous gammaglobulin infusions. Clin Exp Immunol. 1993;92:200–204.

    PubMed  Article  CAS  Google Scholar 

  34. Gardulf A, Nicolay U, Math D, et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol. 2004;114:936–942.

    PubMed  Article  CAS  Google Scholar 

  35. Gardulf A, Borte M, Ochs HD, Nicolay U. Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy. Clin Immunol. 2008;126:81–88.

    PubMed  Article  CAS  Google Scholar 

  36. Nicolay U, Kiessling P, Berger M, et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol. 2006;26:65–72.

    PubMed  Article  CAS  Google Scholar 

  37. Berger M, Murphy E, Riley P, Bergman GE. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G. South Med J. 2010;103:856–863.

    PubMed  Article  Google Scholar 

  38. Shapiro R. Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis. J Clin Immunol. 2010;30:301–307.

    PubMed  Article  CAS  Google Scholar 

  39. Berger M, Pinciaro PJ, Althaus A, et al. Efficacy, pharmacokinetics, safety, and tolerability of Flebogamma 10% DIF, a high-purity human intravenous immunoglobulin, in primary immunodeficiency. J Clin Immunol. 2010;30:321–329.

    PubMed  Article  CAS  Google Scholar 

  40. Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol. 2010;137:21–30.

    PubMed  Article  CAS  Google Scholar 

  41. Berger M. Subcutaneous administration of IgG. Immunol Allergy Clin North Am. 2008;28:779–802, viii.

    PubMed  Article  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Medical Biochemistry and Immunology, University Hospital of Wales, Cardiff, UK

    S. Jolles

  2. Department of Pediatrics, University of South Florida, St. Petersburg, FL, USA

    J. W. Sleasman

Authors
  1. S. Jolles
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. W. Sleasman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. W. Sleasman.

Additional information

This article is published with open access at Springerlink.com

Rights and permissions

This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.

About this article

Cite this article

Jolles, S., Sleasman, J.W. Subcutaneous immunoglobulin replacement therapy with Hizentra®, the first 20% SCIG preparation: a Practical approach. Adv Therapy 28, 521 (2011). https://doi.org/10.1007/s12325-011-0036-y

Download citation

  • Received:

  • Published:

  • DOI: https://doi.org/10.1007/s12325-011-0036-y

Keywords

  • Hizentra
  • subcutaneous IgG treatment
  • IgG
  • replacement therapy
  • primary immunodeficiency